Evidence map›Paper›PMID 38695073›Full record

ArticleAmerican journal of physiology. Renal physiology2024

SGLT2 inhibitors: not every drug has the same effect.

Alexander Staruschenko

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in American journal of physiology. Renal physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Gliflozins in hypertension: basic mechanisms and clinical insights.American journal of physiology. Renal physiology · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Alexander StaruschenkoDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, United States.ORCID 0000-0002-5190-8356

Funding

Sexual dimorphisms and role of the cGAS-STING pathway in diabetic nephropathyR01DK135644 · UNIVERSITY OF SOUTH FLORIDA · 2025 to 2025
$513k
Renal diabetic complications mediated by the PAR1 signaling in podocytesR01DK129227 · UNIVERSITY OF SOUTH FLORIDA · 2025 to 2025
$326k
Transport and metabolism in the kidneyI01BX004024 · VA · JAMES A. HALEY VA MEDICAL CENTER · 2021 to 2025
–
BLRD VA I01 BX004024NIDDK NIH HHS R01 DK135644
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Sodium-Glucose Transporter 2 InhibitorsAnimalsDiabetes Mellitus, Type 2Diabetic NephropathiesHumansHypoglycemic AgentsKidneySodium-Glucose Transporter 2Hypoglycemic AgentsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorscanagliflozinempagliflozinNHE3proximal tubuleSGLT2 inhibitors

Identifiers

PMID38695073

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.